Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting MYCN in Pediatric and Adult Cancers
Zhihui Liu, Samuel S. Chen, Saki Clarke, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Therapeutic targeting of “undruggable” MYC
Víctor Llombart, Marc R. Mansour
EBioMedicine (2021) Vol. 75, pp. 103756-103756
Open Access | Times Cited: 256
The Role of Chronic Inflammation in Pediatric Cancer
Christine Mella, Panogiotis Tsarouhas, Maximillian Brockwell, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 154-154
Open Access | Times Cited: 2
The long journey to bring a Myc inhibitor to the clinic
Jonathan R. Whitfield, Laura Soucek
The Journal of Cell Biology (2021) Vol. 220, Iss. 8
Open Access | Times Cited: 80
MYC assembles and stimulates topoisomerases 1 and 2 in a “topoisome”
Subhendu Das, Vladislav Kuzin, Donald P. Cameron, et al.
Molecular Cell (2021) Vol. 82, Iss. 1, pp. 140-158.e12
Open Access | Times Cited: 68
IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression
Sven Hagemann, Danny Misiak, Jessica L. Bell, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification
Wenjing Shi, Yongzhe Tang, Jing Lu, et al.
Cell & Bioscience (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 38
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
Damiano Bartolucci, Luca Montemurro, Salvatore Raieli, et al.
Cancers (2022) Vol. 14, Iss. 18, pp. 4421-4421
Open Access | Times Cited: 32
Hyperactivation of YAP/TAZ Drives Alterations in Mesangial Cells through Stabilization of N-Myc in Diabetic Nephropathy
Seunghyeok Choi, Seon Pyo Hong, Jung Hyun Bae, et al.
Journal of the American Society of Nephrology (2023) Vol. 34, Iss. 5, pp. 809-828
Open Access | Times Cited: 18
Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma
Muhammad Rishfi, Simon Krols, Fien Martens, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115033-115033
Open Access | Times Cited: 26
Biological Insight and Recent Advancement in the Treatment of Neuroblastoma
Zoriamin Rivera, Carlos Escutia, Mary Beth Madonna, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8470-8470
Open Access | Times Cited: 13
A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma
Patrizia Perri, Mirco Ponzoni, Maria Valeria Corrias, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5528-5528
Open Access | Times Cited: 29
A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle
Hongli Li, Lulu Dong, Min-Jie Jin, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1141-1141
Open Access | Times Cited: 11
MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription
Zhihui Liu, Xiyuan Zhang, Man Xu, et al.
PLoS Biology (2024) Vol. 22, Iss. 3, pp. e3002240-e3002240
Open Access | Times Cited: 4
MYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma
Zhihui Liu, Jason J. Hong, Xiyuan Zhang, et al.
Oncogenesis (2025) Vol. 14, Iss. 1
Open Access
MYCN as an oncogene in pediatric brain tumors
Ana Patiño-Garcı́a, Jennifer Jackson, Prashanth G. Iyer, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
Anna Magdalena Wulf, Marcela M. Moreno, Chloé A. Paka, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11718-11718
Open Access | Times Cited: 25
Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice
Arman Romiani, Klara Simonsson, Dan Pettersson, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e31409-e31409
Open Access | Times Cited: 3
Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002
Anna Lisa Scardovi, Damiano Bartolucci, Luca Montemurro, et al.
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 4, pp. 173-187
Closed Access | Times Cited: 3
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis
Jayne Murray, Emanuele Valli, Giorgio Milazzo, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma
Kausik Bishayee, Uddin Md. Nazim, Vijay Kumar, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 113032-113032
Open Access | Times Cited: 15
Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma
Soraya Epp, Shin Mei Chuah, Melinda Halász
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 17085-17085
Open Access | Times Cited: 8
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
Laura V. Bownes, Raoud Marayati, Colin H. Quinn, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1952-1952
Open Access | Times Cited: 13
Pharmacophore-Model-Based Virtual-Screening Approaches Identified Novel Natural Molecular Candidates for Treating Human Neuroblastoma
F A Dain Md Opo, Saleh Alkarim, Ghadeer I. Alrefaei, et al.
Current Issues in Molecular Biology (2022) Vol. 44, Iss. 10, pp. 4838-4858
Open Access | Times Cited: 13
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance
Sonia Bortolotti, Silvia Angelucci, Luca Montemurro, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 990-990
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top